An intrathecal bleed is an exceedingly rare, yet
potentially devastating consequence of accessing
the epidural space for lead placement during a
spinal cord stimulator trial. We present a case of
radiologic evidence of intrathecal blood products
and the neurologic consequences thereof following
a percutaneous spinal cord stimulator trial.
A 34-year-old man with a primary diagnosis
of failed back surgery syndrome underwent
percutaneous spinal cord stimulator lead placement.
During the trial, the patient experienced
paresthesia with initial right-side lead placement
at T12-L1. The lead and needle were removed
and placed at L1-2 where the patient did not
report any problems. The patient reported right
calf pain in the postanesthesia care unit following
the trial that improved with intravenous
hydromorphone. However, following discharge
the patient experienced worsening dysesthesia
with edema of the right lower extremity to the calf.
Magnetic resonance imaging of the lumbar spine
confirmed the presence of blood products within
the intrathecal space.
Spinal cord stimulator placement may be viewed
as a safe and effective treatment modality despite
the incidence of several neurologic, mechanical,
and biologic complications. A few case reports
discuss the occurrence of spinal epidural hematoma
formation but none present a case of an
intrathecal bleed following percutaneous spinal
cord stimulator lead placement. This case report
highlights the need to further elucidate the incidence
of neurologic sequelae after spinal cord
stimulator placement.
Key words: Spinal cord stimulation, antiplatelets,
anticoagulation, intrathecal bleed, complications,
failed back surgery syndrome